AU2003266827B2 - Random drift mutagenesis - Google Patents
Random drift mutagenesis Download PDFInfo
- Publication number
- AU2003266827B2 AU2003266827B2 AU2003266827A AU2003266827A AU2003266827B2 AU 2003266827 B2 AU2003266827 B2 AU 2003266827B2 AU 2003266827 A AU2003266827 A AU 2003266827A AU 2003266827 A AU2003266827 A AU 2003266827A AU 2003266827 B2 AU2003266827 B2 AU 2003266827B2
- Authority
- AU
- Australia
- Prior art keywords
- enzyme
- gene
- substrate
- mutant
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 231100000350 mutagenesis Toxicity 0.000 title claims description 22
- 238000002703 mutagenesis Methods 0.000 title claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 142
- 238000000034 method Methods 0.000 claims description 81
- 102000004190 Enzymes Human genes 0.000 claims description 52
- 108090000790 Enzymes Proteins 0.000 claims description 52
- 239000000758 substrate Substances 0.000 claims description 38
- 238000003752 polymerase chain reaction Methods 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 11
- 238000000684 flow cytometry Methods 0.000 claims description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 10
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical group C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 238000010348 incorporation Methods 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 102000005575 Cellulases Human genes 0.000 claims description 5
- 108010084185 Cellulases Proteins 0.000 claims description 5
- 230000009471 action Effects 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 5
- -1 5-Bromo-4-chloro-3-indolyl Chemical group 0.000 claims description 4
- 102000004157 Hydrolases Human genes 0.000 claims description 4
- 108090000604 Hydrolases Proteins 0.000 claims description 4
- 238000009630 liquid culture Methods 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 claims description 3
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 3
- 108010055059 beta-Mannosidase Proteins 0.000 claims description 3
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 3
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003147 glycosyl group Chemical group 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 2
- 102000001696 Mannosidases Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 108010038658 exo-1,4-beta-D-xylosidase Proteins 0.000 claims description 2
- 230000003595 spectral effect Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 54
- 229940088598 enzyme Drugs 0.000 description 42
- 239000000047 product Substances 0.000 description 35
- 244000005700 microbiome Species 0.000 description 31
- 230000035772 mutation Effects 0.000 description 25
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- 231100000219 mutagenic Toxicity 0.000 description 10
- 230000003505 mutagenic effect Effects 0.000 description 10
- 238000009825 accumulation Methods 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 229940097275 indigo Drugs 0.000 description 7
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 7
- 101150100570 bglA gene Proteins 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 241000863389 Dictyoglomus thermophilum Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000003044 adaptive effect Effects 0.000 description 5
- 239000003068 molecular probe Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000002655 kraft paper Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 101150031048 xynB gene Proteins 0.000 description 3
- 241000863390 Dictyoglomus Species 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- 229920001131 Pulp (paper) Polymers 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000004076 pulp bleaching Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- ZTOBILYWTYHOJB-LWXMCBIJSA-N 3',6'-bis[[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]spiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C3(C4=CC=CC=C4C(=O)O3)C3=CC=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC2=C1 ZTOBILYWTYHOJB-LWXMCBIJSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-YGEXGZRRSA-N 5-bromo-4-chloro-3-indolyl alpha-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-YGEXGZRRSA-N 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 241000178335 Caldicellulosiruptor saccharolyticus Species 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001317 epifluorescence microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- SLIWIQKBDGZFQR-PIVCGYGYSA-N n-[3-oxo-3',6'-bis[[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy]spiro[2-benzofuran-1,9'-xanthene]-5-yl]dodecanamide Chemical compound C=1C(NC(=O)CCCCCCCCCCC)=CC=C2C=1C(=O)OC2(C1=CC=C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)C=C1OC1=C2)C1=CC=C2O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O SLIWIQKBDGZFQR-PIVCGYGYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
WO 2004/031387 PCT/AU2003/001314 RANDOM DRIFT MUTAGENESIS Technical Field The present invention is directed to methods for producing mutant genes and mutant gene products.
Background Art There are many situations such as medical, veterinary and industrial applications, where mutant gene products are desirable. Microorganisms can produce a great variety of proteins, particularly enzymes, which can be used in may situations. Many of these proteins, however, have characteristics that are not ideal for subsequent use and therefore it is desirable to obtain mutants with altered activity or functions. There are a number of methods and techniques presently in use which can generate mutant genes and corresponding mutant gene products.
Stemmer (Stemmer, W. P. C. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370, 389 391, 1994.; Stemmer, W. P. C. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. Proc. Natl.
Acad. USA 91, 10747 10751, 1994) has discussed the most effective methods to search sequence space in vitro to yield the greatest diversity of protein variants. Until recently, the most popular methods of creating combinatorial libraries are recursive strategies that seek to evolve sequences by the addition of point mutations (Cadwell and Joyce. Randomization of genes by PCR mutagenesis. PCR Methods Appl. 2: 28 33, 1992). For in vitro evolution, inclusion of recombinant polymerase chain reaction PCR (gene shuffling) offers practical and theoretical advantages over simple recursive point mutagenesis methods. It will rapidly fine tune the mutational load in several parts of the protein by recombining point mutations and wild-type sequences. The technique (and its variations) have been used to enhance enzyme activity, substrate specificity and stability. Gene shuffling is usually achieved by fragmentation of the genes to be shuffled followed by PCR. This method relies on homologous recombination during the PCR reassembly step. Most methods require relatively high levels of sequence similarity between the genes to be shuffled as 'cross-over points' appear to occur in these regions.
If sequence similarity is low between the input genes, the majority products tend to be the reassembled parental genes and extensive searches need to be carried out to find recombinants (Kikuchi, Ohnishi, K. Harayama, S. Novel family shuffling methods for the in vitro evolution of enzymes. Gene 236, 159 167, 1999; Ostermeier, Shim, J. H. Benkovic, S. J. A combinatorial approach to hybrid enzymes WO 2004/031387 PCTiAU20031001314 2 independent of DNA homology. Nat. Biotechnol. 17, 1205 1209, 1999.). Kichuchi et al (1999) have reported on methods for gene shuffling that make use of unique restriction enzyme sites in the sequences of the parental molecules and following cleavage, several PCR steps were carried out to amplify the recombinant genes, a process that allowed hybrid genes tobe formed at high frequency.
An entirely different procedure was proposed by Ostermeier et al (1999) that allowed the preparation of combinatorial fusion libraries by progressive truncation of coding sequences of the two parental sequences followed by ligation of the fragments and selection for enzyme activity. Either parent can be used to provide 5' sequence for the hybrid gene. This procedure, termed iterative truncation for the creation of hybrid enzymes (ITCHY), can accommodate recombination between genes with as little as sequence similarity and was found to give a wider range of crossovers compared with standard gene shuffling techniques.
The present applicant has isolated a gene coding for a thermophilic beta-xylanase that had improved performance in the bleaching of paper pulp. It was desired to investigate the possibility of obtaining mutant derivatives that had enhanced stability and an altered pH optimum. Experiments using error-prone PCR and mis-incorporation mutagenesis followed by gene shuffling allowed the identification of mutant genes that coded for a limited sample of the variations in sequence space but required extensive screening for their identification. Gene shuffling following DNAsel fragmentation of related genes (family shuffling) overwhelmingly gave wild type parental sequences as the major products. After several trials of methods designed to reduce the background, a technique was devised that allows shuffling of genes that differ widely in sequence similarity and G:C content and greatly reduces the appearance of wild type genes.
Furthermore, the primer extension conditions may be modified to bias the resulting progeny genes towards any one (or more) of the parental input genes. The present applicant termed this procedure Degenerate Oligonucleotide Gene Shuffling (DOGS) which is described in WO 02/18629.
Although there are many options available to generate mutants, those methods do not necessarily result in useful products or may be too time consuming or unsuccessful. The present inventors have now developed a new method capable of producing potentially many different functional mutants.
WO 2004/031387 PCTiAU20031001314 3 Disclosure of Invention In a first aspect, the present invention provides a method for producing a mutant gene encoding a functional gene product, the method comprising: introducing one or more mutations into a gene to form a mutated gene; providing the mutated gene to a host microorganism; culturing the host microorganism containing the mutated gene under conditions which allow expression of the mutant gene product; and selecting a host microorganism capable of producing a functional gene product from the mutated gene.
In a preferred form, the method comprises: introducing one or mutations into a gene to form a plurality of mutated genes; providing the mutated genes to host microorganisms; culturing the host microorganisms containing the mutated genes under conditions which allow expression of the mutant gene products; and selecting host microorganisms capable of producing a functional gene product from a mutated gene.
In a preferred form, the method further comprises: obtaining a combined pool of mutated genes encoding functional gene products from the microorganisms in step and repeating steps to to form a library of microorganisms containing a plurality of mutant genes capable of being expressed and producing functional gene products.
In another preferred form, the method further comprises: screening the library of microorganisms to obtain a mutant gene capable of expressing a mutant gene product.
Preferably, the mutant gene product has an altered or desired activity, function, or characteristic compared with the native gene product.
Preferably, step is carried out by mis-incorporation mutagenesis using polymerase chain reaction (PCR). It will be appreciated, however, that other methods known to the art to introduce one or mutations into a gene would also be suitable. An example includes, but is not limited to, gene shuffling.
WO 2004/031387 PCT/AU2003/001314 4 Preferably, step is carried out by ligating the mutant gene into a vector and transforming a bacterium with the vector. Methods of introducing gene(s) into microorganisms are well known to the art and would be applicable for the present invention. The vector may be a plasmid or virus, for example. A microorganism particularly suitable for this step in the bacterium Escherichia coli. It will be appreciated that other host microorganisms could also be used for this step.
Preferably, the host microorganisms are cultured under conditions in which the native gene would be expected to be expressed in the particular host microorganism.
Liquid culture is particularly suitable for this step as it allows easy retrieval of the cultured microorganisms for subsequent use or analysis. It will be appreciated, however, that any suitable culturing means can be used in this step such as those found in Morris et al.
Cloning of the xynB gene from Dictyoglomus thermophilum strain Rt46B.1 and action of the gene-product on kraft pulp. Appl. Environ. Microbiol. 64:1759 1765, 1998; Gibbs et al. Cloning, sequencing and expression of a xylanase gene from the extreme thermophile Dictyoglomus Rt46B.1 and the activity of the enzyme on fibre-bound substrate. Appl. Environ. Microbiol. 61:4403 -4408, 1995 (incorporated herein by reference).
In a further preferred form, the culture conditions result in any host microorganism capable of expressing a functional gene having a detectable characteristic. One preferred form of a detectable characteristic is a selectable phenotype. Examples include colour, size, shape, fluorescence, dependency on a supplied metabolite for growth, enzymatic activity such as enzymatic conversion of a supplied substrate which would allow selection based upon colour or fluorescence. In a more preferred form, the gene encodes an enzyme that can form a fluorometric or chromogenic phenotype or character in a microorganism expressing the gene preferably under appropriate conditions.
In a more preferred form, the gene encodes an enzyme which can form a fluorometric or chromogenic phenotype or character in a microorganism expressing the gene under liquid culture conditions.
The present invention is particularly suitable for high volume screening using a sorting or selecting instrument such as a cell sorter or cytometer. Many different enzymes can act on a substrate to produce a coloured product. When the substrate is acted upon in a cell, the cell may change colour which is then detectable. Accordingly, under the appropriate cultural conditions, microorganisms which express a functional WO 2004/031387 PCTiAU2003/001314 gene product will be coloured and therefore selectable over other microorganisms which do not produce a functional product.
A difference between the present invention and other methods for obtaining mutant genes is that it does not apply any selective pressure or testing for altered activity of the mutant gene products during the process, apart from the retention of function by the mutated gene product.
A further difference between the present invention and other methods for obtaining mutant genes is that it does not select for the removal of neutral mutations or mutations which reduce but do not eliminate the function of the mutated gene product.
The method according to the present invention can be used to produce potentially a large number of different mutant genes encoding functional gene products with potentially large numbers of mutations which can then be tested for altered characteristics or desired qualities or function.
In a preferred form, the gene product is an enzyme. More preferably, the enzyme is capable of acting on an X-sugar or a fluorescein-linked sugar such as Imagene Green
(C
12 FDG, Molecular Probes, Eugene, OR, USA). The enzyme is preferably capable of acting on a substrate such as X-gal which forms a chromogen upon enzymatic hydrolysis, X-gal being defined as 5-Bromo-4-chloro-3-indolyl -D-galactopyranoside.
In a further preferred form, the gene product substrate should be retained on, or within the cell, in liquid culture.
In a second aspect, the present invention provides a mutant gene capable of producing a mutant gene product produced by the method according to the first aspect of the present invention.
In a third aspect, the present invention provides a method for producing a mutant gene encoding a functional enzyme, the method comprising: introducing one or more mutations into a gene encoding the enzyme to form a plurality of mutated genes; incorporating the mutated genes into vectors; transforming host microorganisms with the vectors; culturing the host microorganisms containing the mutated genes under conditions which would allow expression of the corresponding native gene to produce the native enzyme such that the microorganisms express the mutant genes; WO 2004/031387 PCTiAU20031001314 6 providing a substrate upon which the enzyme can act to produce a selectable phenotype in any host bacterium producing a functional enzyme; and selecting host microorganisms capable of producing a functional gene product from the mutated gene by sorting bacteria having the selectable phenotype.
In a preferred form, the method further comprises: obtaining a pool of mutated genes from the microorganisms in step and repeating steps to to form a library of microorganisms containing a plurality of multiply-mutant genes capable of being expressed and producing functional enzymes.
In another preferred form, the method further comprises: screening the library of microorganisms to obtain a mutant gene capable of expressing an enzyme with an altered or desired activity, function, or characteristic.
Preferably, the microorganisms are bacteria. A suitable bacterium is Escherichia coil, although other suitable host bacteria can be used.
Preferably the sorting is done by fluorescence activated cell sorting (FACS) using flow-cytometry and the bacteria selected by changes in their spectral or fluorescence characteristics due to action of the functional enzyme on the substrate.
In a fourth aspect, the present invention provides a mutant gene capable of producing a mutant gene product produced by the method according to the third aspect of the present invention.
In a fifth aspect, the present invention provides a method for obtaining a mutant or chimeric gene comprising: to carrying out the steps according to the first aspect of the present invention to obtain a mutant gene; providing the mutant gene to a host microorganism; and carrying out a further mutagenic step to obtain a mutant or chimeric gene.
It will be appreciated that any suitable mutagenic process in step would be suitable. Examples include, but not limited to, gene shuffling or degenerate oligonucleotide gene shuffling, or mutagenic polymerase chain reaction (PCR).
In a preferred embodiment, step comprises: assigning one or more segments of the mutant gene based on regions of shared encoded amino acid sequence; WO 2004/031387 PCT/AU2003/001314 7 (ii) amplifying the one or more assigned segments of the gene using a primer having a non-degenerate core based on a segment or template of a gene to be amplified, and the core being flanked by both 5' and 3' ends which, if required, are degenerate; and (iii) causing recombination of the one or more amplified segments to form a mutant or chimeric gene.
In a sixth aspect, the present invention provides a mutant or chimeric gene produced by the method according to the fifth aspect of the present invention.
In a seventh aspect, the present invention provides a method for obtaining a mutant or chimeric gene encoding an enzyme, the method comprising: to carrying out the steps according to the third aspect of the present invention to obtain a mutant gene encoding an enzyme; providing the mutant gene to a host microorganism; and carrying out a further mutagenic step to obtain a mutant or chimeric gene encoding an enzyme.
It will be appreciated that any suitable mutagenic process in step would be suitable. Examples include, but not limited to, gene shuffling or degenerate oligonucleotide gene shuffling, or mutagenic PCR (Gibbs et al. Degenerate oligonucleotide gene shuffling (DOGS): A method for enhancing the frequency of recombination with family shuffling Gene 271: 13 20, 2001. A review of other suitable directed evolution methods can be found in Farinas et al. Directed Enzyme Evolution.
Current Opinion in Biotechnology 12: 545 551, 2001 (incorporated herein by reference).
In a preferred embodiment, step comprises: assigning one or more segments of the mutant gene based on regions of shared encoded amino acid sequence; (ii) amplifying the one or more assigned segments of the gene using a primer having a non-degenerate core based on a segment or template of a gene to be amplified, and the core being flanked by both 5' and 3' ends which, if required, are degenerate; and (iii) causing recombination of the one or more amplified segments to form a mutant or chimeric gene encoding an enzyme.
WO 2004/031387 PCT/AU2003/001314 8 In an eighth aspect, the present invention provides a mutant or chimeric gene encoding an enzyme produced by the method according to the seventh aspect of the present invention.
The methods according to the present invention are particularly applicable to the directed evolution of any gene/enzyme capable of hydrolysing a synthetic target substrate with fluorogenic properties.
The substrate could be any indoxyl-linked compound. However, any other chromogenic or fluorogenic substrate that is retained in the cell subsequent to hydrolysis, and can be detected by flow cytometry or other means, would be suitable.
Many indoxyl-linked substrates are commercially available as substrates for many glycosyl hydrolases, including, cellulases, beta-glucosidases, beta-galactosidases, mannosidases, xylanases and beta-xylosidases. Substrates are also available for esterases and/or lipases.
Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but ndt the exclusion of any other element, integer or step, or group of elements, integers or steps.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.
In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following drawings and examples.
Brief Description of the Drawings Figure 1. Random Drift flow diagram outlining the basic concept of random drift mutagenesis.
Figure 2. X-sugar detailing the diffusion of a substrate-linked indoxyl such as Xgal into E. coli, followed by enzymatic cleavage to form an insoluble chromogenic Indigo precipitate within the cell.
WO 2004/031387 PCT/AU2003/001314 9 Figure 3. Flow diagram of cell sorting by FACS flow cytometry (excitation 488, emission FL1 515-565 nm) based upon expression of BglA phenotype and accumulation of insoluble Indigo within E. coli DH5-alpha cells containing the plasmid pProEXHTc:bglA. A. Sorting of E. coli cell populations containing either the plasmid pProEXHTc:bglA or pProEXHTc in the presence or absence of the chromagenic substrate X-gal. Key: Red: Cells expressing BgIA in the presence of X-gal Blue: Cells expressing BglA in the absence of X-gal Green: Control cells (vector only) in the presence of X-gal Magenta: Control cells (vector only) in the absence of X-gal B. Part 1. Overlayed datasets from part A showing the clear dilineation between cell populations expressing the BglA+ phenotype (red) vs BglA- phenotype (green). Parts 2 and 3. Overlayed datasets from part A showing that presence or absence of X-gal did not contribute to observed effects. The data shows that this Indigo precipitate can be detected within coli by FACS techniques.
Figure 4. Showing cell population sorting by FACS flow cytometry (excitation 488, emission FL1 515-565 nm) based upon expression of BgIA phenotype and accumulation of Imagene Green within the BglA+ cells. The results show a clear delineation of cell populations expressing the BglA+ phenotype (circled) vs BglAphenotype (uncircled) based upon cell fluorescence due to the hydrolysis of Imagene Green within each cell by BglA.
Figure 5. Epi-fluorescence microscopy of DH5-alpha cells transformed with pProEXHTc:bglA (BglA+) following a 5 minute 65 0 C heat shock in the presence of Imagene green. The cellular fluorescence is due to the hydrolysis of Imagene green which has diffused into the cell during the heat shock step.
Mode(s) for Carrying Out the Invention The present inventors have developed a new procedure for achieving directed evolution of proteins, particularly enzymes, which are more suited to novel environments and applications than their natural counterparts. The method is particularly adaptable for utilising flow cytometry and chromogenic or fluorogenic substrates. The method allows repeated rounds of in vitro mutation and recombination between selected mutants, followed by screening for isolates with an altered pH optimum for activity and selection of WO 2004/031387 PCT/AU2003/001314 the most fit survivors. One particular use resulted in the isolation of novel glycosyl hydrolases with superior enzymatic specifications, their expression, and evaluation for their industrial potential, i.e. pH suitability.
The present applicant has also developed a novel method for the in vitro evolution of proteins called Degenerate Oligonucleotide Gene Shuffling (DOGS) (WO 02/18629, incorporated herein by reference). The DOGS method was designed for shuffling genes from different families, but it has now been found that it is applicable to random mutations of a single gene so that the limits of sequence space can be explored.
This is performed by mis-incorporation mutagenesis during PCR synthesis of a copy of the target gene. The iterative screening of mis-incorporation mutagenesis libraries with low mutation frequencies (1-2 amino acid changes/protein) allows the stepwise accumulation of adaptive mutations. Stepwise accumulation of single mutations allows the sampling of a far larger functional sequence space than if highly mutated recombinants are screened. As a consequence, mis-incorporation mutagenesis tends to select for adaptive mutations while discarding neutral mutations or mutations which decrease the fitness of an enzyme.
Phenotypes such as thermostability can be readily improved by iterative incorporation of single mutations. The present inventors have developed a technique to determine whether a phenotype that is derived from the interaction of multiple amino acids (in this case, an enzyme's pH optimum) might require the accumulation and interaction of neutral mutations (neutral in isolation), and adaptive mutations. A preferred form of the method according to the present invention uses iterative mis-incorporation mutagenesis in the normal manner. However, no screening for adaptive mutations occurs or is required. Instead, screening is only done for retained ability (whether unchanged, improved or reduced) to catalyse the hydrolysis of a substrate. All positive recombinants would be combined and used as template for a further round of mutagenesis and so on for as many rounds as are necessary. In this manner, it is assumed that accumulation of multiple adaptive, neutral and harmful (but not inactivating) mutations would occur. Once generated, this library can then be screened for enzymes with modified pH optima, for example. Recombinants with the desired phenotype optionally can then be backcrossed with the parental wild-type gene using DOGS to remove any mutations not contributing to the altered phenotype.
WO 2004/031387 PCT/AU2003/001314 11
PROCEDURE
Figure 1 shows a schematic of a method for random drift mutagenesis according to the present invention. Step 1 involves mutagenic PCR of a number of copies of a gene encoding an enzyme to form a plurality of mutant genes. The mutated genes are then ligated into plasmids and transformed into E. coli. The bacteria are then cultured in selective media that contains a substrate which, when acted upon by any functional enzyme in the cell will cause the cell to have a detectable phenotype. The cultured cells are then sorted by a flow cytometer and cells having the phenotype induced by the enzyme are selected. All selected cells will contain a gene encoding a functional enzyme. Plasmid DNA can be obtained from any of the cells and processed again through the method to obtain further mutants. After a number of rounds of mutagenesis and cell selection, individual mutants can be screen for enzymes having a desired or altered characteristic. The mutants can be further mutated or crossed by other means.
EXAMPLES
The experiment used the gene for a thermostable enzyme and a relatively inexpensive substrate. The method was also be applied it to the gene for Dictyoglomus XynB enzyme (Morris et al. Cloning of the xynB gene from Dictyoglomus thermophilum strain Rt46B.1 and action of the gene-product on kraft pulp. Appl. Environ. Microbiol.
64:1759 1765, 1998) that is a candidate in the pulp bleaching area (and would use a custom-synthesized substrate in the mutagenesis experiments).
Experimental and Techniques Gene: Caldicellulosiruptor saccharolyticus R-glucosidase, bglA (Love et al.
Sequence structure and expression of a cloned B-glucosidase from an extreme thermophile. Mol Gen Genet 213: 84 92, 1988); Substrate: aI-D-chloroindolylgalactoside (X-gal) or l9-D-chloroindolyl-glucose (X-glu). Cleavage of these commercial substrates by hydrolases such as BglA results in the precipitation of insoluble indigo, in our case, inside the cell. For all experiments the bglA gene was ligated in-frame into the expression vector pProEXHTc (Invitrogen, CA, USA) and transformed into E. coli alpha. Detectable levels of BgIA gene product were produced using the substrates X-gal and C12FDG. No induction with IPTG was required due to low levels of constitutive expression from the pProEXHTc TAC promoter.
WO 2004/031387 PCT/AU2003/001314 12 Steps: PCR mutagenesis of BglA gene to give 1-2 changed amino acids per recombinant gene (Cadwell and Joyce. Randomization of genes by PCR mutagenesis.
PCR methods AppI 2: 28 33, 1992). Mutagenic PCR was achieved using 5 units Amplitaq (Perkin Elmer), a final concentration of 1 x Amplitaq PCR buffer, 7 mM MgCL 2 0.2 mM dGTP, 0.2 mM dATP, 1 mM dCTP, 1 mM dTTP, 0.5 mM MnCI 2 0.2 pM forward primer, 0.2pM reverse primer, and 0.1 ng bgIA template in a final volume of 50 pl.
(ii) Ligate mutagenic PCR product into vector and transform into Alac host. The restriction sites Ncol and BamHI were incorporated into the forward and reverse primers respectively to allow restriction digest of the bglA PCR product, and directional ligation into pProEXHTc predigested with the same restriction enzymes. Ligation mixtures were transformed into highly competent E. coli DH5-alpha (5 x 108 cfu pg DNA, Invitrogen).
(iii) Outgrow transformation mix in LB+ X-gal (0.2 mg ml)+ Ampicillin (60 pg ml) to allow expression of BglA and hydrolysis of X-gal. Sort cells by FACS flow cytometry into those containing indigo (BglA"), and those without (BglA-) by detection of emission at 515-565 nm..
(iv) Take BglA cells, release plasmid DNA by heating cells at 95 0 C for 15 minutes.
Go to step and repeat. Use released plasmid DNA as template for next round of mutagenic PCR.
(vi) At the end of each round, plate a portion of the recombinants, check they are still active (check also ratio of +ve to -ve to confirm sorting procedure) and sequence some recombinants to determine level of accumulation of mutations.
Steps to (vi) usually can be done in 1 to 2 days. This technique allows selection from about 106 potential mutants at each round of cell-sorting. If only 10% of single point mutation mutants retain activity, then potentially 10 5 mutants can be sorted and retained at each round. This method allows the rapid selection of recombinants with multiple mutations and eliminates tedious screening procedures.
The present inventors have found that the fluorescent beta-galactosidase/betaglucosidase substrate Imagene Green (C 12 FDG, Molecular Probes, USA) is a good substrate for flow cytometry detection of E. coli cells expressing the BglA+ phenotype.
This substrate can be directly substituted for X-gal in the examples of the methods according to the present invention.
WO 2004/031387 PCT/AU2003/001314 13 The present inventors have shown that the hydrolysis product of X-gal can be used to sort cells based upon the accumulation of indigo within those cells expressing the BglA+ phenotype. Figure 2 shows the chemical reaction by enzymatic hydrolysis of the chromogenic substrate in the cell causing a color change to the bacterial cell with a functional enzyme.
Figure 3 shows that these indigo-labelled cells can be readily distinguished from unlabelled cells using a Becton Dickinson FACS Calibur Flow cytometry system employing an Argon ion 488 nm laser, using the FL1 emission filter (515- 565 nm).
Figure 4 shows cell population sorting by FACS flow cytometry (excitation 488, emission FL1 515-565 nm) based upon expression of BglA phenotype and accumulation of Imagene Green within the BglA+ cells. The results show a clear delineation of cell populations expressing the BglA+ phenotype (circled) vs BglA- phenotype (uncircled) based upon cell fluorescence due to the hydrolysis of Imagene Green within each cell by BglA.
Furthermore, the present inventors have found that fluorescent labelling of BglA+ cells in the presence of Imagene Green was significantly enhanced if the cells were heated to 650C for 5 minutes in the presence of the Imagene green substrate. In this case, DH5-alpha cells transformed with pProEXHTa:bg/A were outgrown in LB Ampicillin (60 pg ml) for approximately 10 hours. Cells were harvested by centrifugation, then resuspended in water containing 10 pM Imagene green, and heated to 65°C for 5 minutes in waterbath. Cells were then centrifuged, and the pellet resuspended in water without substrate. Figure 5 shows an epi-fluorescence microscope image (Axioskop 2 microscope, Zeiss, Germany, excitation 450-490 nm) of BglA+ E. coli cells labelled with Imagene Green. The observed fluorescence is due to the hydrolysis of Imagene green that has diffused into the cell. Heating of the cells is presumed to reduce the membrane potential of the E. coli cell wall allowing rapid diffusion of Imagene Green into the cell where it can then be hydrolysed by BglA.
Outcomes Potentially any substrate that can accumulate within a cell and be detected by fluorescence could be used for sorting. All of the X-substrates such as X-gal and X-glu could be used as they accumulate as indigo within cells. Potentially, we could have Xxylobiose synthesised (X-cellobiose is commercially available so this is technically feasible) to use in xylanase mutagenesis for further improvement of the performance of WO 2004/031387 PCT/AU2003/001314 14 XynB from Dictyoglomus thermophilum. Potentially, many sugars could be labelled with fluoroscein in the manner of Imagene Green for use for random drift mutagenesis.
Currently substrates have been synthesised for beta-glucuronidases (FDGIcU, Molecular Probes), beta-glucosidases (FDGlu, Molecular Probes) and glucocerebrosidases (BIODIPY FL C 12 -glucocerebroside, Molecular Probes)Potentially, fluorescein labelled xylobiose could be synthesized to be used in xylanase mutagenesis for further improvement of the performance of XynB from Dictyoglomus thermophilum in wood pulp bleaching applications where enzymes must function under high temperature and highly alkaline conditions (Morris et al. Cloning of the xynB gene from Dictyoglomus thermophilum strain Rt46B.1 and action of the gene-product on kraft pulp. Appl. Environ.
Microbiol. 64:1759 1765, 1998). Furthermore, many other carbohydrate degrading enzymes which are already used in commercial processes, including mannanases, dextranases, pullulanases and amylases, may be suitable candidates for improvement by random drift mutagenesis if fluoroscein-linked substrates can be synthesised.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
Claims (13)
- 2. The method according to claim 1 further comprising: recovering the vectors from the host bacteria expressing a functional enzyme.
- 3. The method according to claim 2 further comprising: screening the library of bacteria to obtain a mutant gene encoding a functional enzyme.
- 4. The method according to any one of claims 1 to 3 wherein step is carried out by mis-incorporation mutagenesis using polymerase chain reaction (PCR) or gene shuffling.
- 5. The method according to any one of claims 1 to 4 wherein the vector is a plasmid or virus.
- 6. The method according to any one of claims 1 to 5 wherein the bacterium is Escherichia co/i.
- 7. The method according to any one of claims 1 to 6 wherein host bacteria are cultured in a liquid medium.
- 8. The method according to any one of claims 1 to 7 wherein the enzyme forms a fluorometric or chromogenic phenotype or character in the host bacteria. C( 9. The method according to any one of claims 1 to 8 wherein the host bacteria is selected by changes in its spectral or fluorescence characteristics due to action of Z the enzyme on the substrate. The method according to any one of claims 1 to 9 wherein the enzyme is capable of acting on a 5-Bromo-4-chloro-3-indolyl-linked sugar substrate or a fluorescein-linked sugar substrate. 0 0
- 11. The method according to claim 10 wherein the substrate is an indoxyl-linked I compound.
- 12. The method according to claim 11 wherein the enzyme acting on an indoxyl-linked S 10 substrate is selected from the group consisting of glycosyl hydrolases, cellulases, beta-glucosidases, beta-galactosidases, mannosidases, xylanases, and beta- xylosidases.
- 13. The method according to claim 12 wherein the enzyme is capable of acting on Bromo-4-chloro-3-indolyl -D-galactopyranoside which forms a chromogen upon enzymatic hydrolysis.
- 14. The method according to any one of claims 1 to 13 wherein the enzyme substrate is retained on, or within the cell, in liquid culture. The method according to any one of claims 1 to 14 wherein flow cytometry is fluorescence activated cell sorting (FACS).
- 16. A mutant gene encoding a functional enzyme, wherein the gene is produced by the method according to any one of claims 1 to
- 17. A library of bacteria comprising a plurality of vectors containing mutated genes encoding an enzyme produced by the method according to any one of claims 1 to
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003266827A AU2003266827B2 (en) | 2002-10-04 | 2003-10-07 | Random drift mutagenesis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002951899A AU2002951899A0 (en) | 2002-10-04 | 2002-10-04 | Random drift mutagenesis |
AU2002951899 | 2002-10-04 | ||
AU2003266827A AU2003266827B2 (en) | 2002-10-04 | 2003-10-07 | Random drift mutagenesis |
PCT/AU2003/001314 WO2004031387A1 (en) | 2002-10-04 | 2003-10-07 | Random drift mutagenesis |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003266827A1 AU2003266827A1 (en) | 2004-04-23 |
AU2003266827B2 true AU2003266827B2 (en) | 2007-12-20 |
Family
ID=34275709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003266827A Ceased AU2003266827B2 (en) | 2002-10-04 | 2003-10-07 | Random drift mutagenesis |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2003266827B2 (en) |
-
2003
- 2003-10-07 AU AU2003266827A patent/AU2003266827B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2003266827A1 (en) | 2004-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7504207B2 (en) | Random drift mutagenesis | |
Tao et al. | Milestones in directed enzyme evolution | |
US11066662B2 (en) | Methods for the production of libraries for directed evolution | |
EP1029040B1 (en) | Method of increasing efficiency of directed evolution of a gene using phagemid | |
EP0285123A2 (en) | A method for complete mutagenesis of nucleic acids | |
Ramirez-Chamorro et al. | Strategies for bacteriophage T5 mutagenesis: expanding the toolbox for phage genome engineering | |
CN113061608B (en) | A method for the evolution of an inducible promoter and its application | |
CN102027112A (en) | Method of nucleic acid recombination | |
Bergquist et al. | Degenerate oligonucleotide gene shuffling (DOGS) and random drift mutagenesis (RNDM): Two complementary techniques for enzyme evolution | |
JP2006500934A5 (en) | ||
AU2003266827B2 (en) | Random drift mutagenesis | |
AU2001283710B2 (en) | Degenerate oligonucleotide gene shuffling | |
JP4479199B2 (en) | Method for producing plasmid containing inserted DNA unit | |
JP2009502158A (en) | Methods for identifying genes that increase stress tolerance in yeast and their use for yeast strain improvement | |
US6630329B2 (en) | Random truncation and amplification of nucleic acid | |
AU2001283710A1 (en) | Degenerate oligonucleotide gene shuffling | |
US20050009080A1 (en) | Production of enzymes having desired activities by mutagenesis | |
EP3940069A1 (en) | Methods for modulating cas-effector activity | |
US20020177691A1 (en) | Trans inteins for protein domain shuffling and biopolymerization | |
Stevenson et al. | Combinatorial approaches to engineering hybrid enzymes | |
US9903873B2 (en) | Method for selecting stable proteins in non-standard physicochemical conditions | |
Shuffling | NSW 2109 Australia Phone:+ 61 2 9850 8614 Fax:+ 61 2 9850 9748 Email: peter. bergquist@ mq. edu. au | |
KR100984644B1 (en) | Target protein-induced evolution in cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |